(2026). Survival Outcomes and Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated First-Line mFOLFOXIRI Plus Bevacizumab: A Real-World Study in Vietnam. OncoTargets and Therapy.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Survival Outcomes and Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated First-Line MFOLFOXIRI Plus Bevacizumab: A Real-World Study in Vietnam."
OncoTargets and Therapy 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Survival Outcomes and Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated First-Line MFOLFOXIRI Plus Bevacizumab: A Real-World Study in Vietnam."
OncoTargets and Therapy, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.